November is Alzheimer Awareness Month and USC is taking on one of the toughest diseases. Alzheimer’s begins 20 years or more before memory loss and is a growing epidemic. Every 65 seconds, someone in America develops Alzheimer and there’s approximately 500,000 new cases diagnosed each year. Today, more than 6 million Americans are living with the disease and that number is expected to soar to 14 million by 2050. The Keck School of Medicine of USC has four world-renowned research centers and institutes focused on this devastating disease. Taking a multi-angled approach from basic research to leading the charge on breakthrough treatments and prevention measures, learn more about their impactful and cutting-edge work:
The Alzheimer Disease Research Center at USC (ADRC) works to understand the biological changes that may precede worsening memory and to assess whether new treatments, including drugs, may be helpful in preventing memory or delay memory loss.
USC’s Mark and Mary Stevens Neuroimaging and Informatics Institute (USC Stevens INI) applies innovative imaging and information technologies to the study of the brain. We share our data and resources with thousands of collaborators around the world.
The mission of the Alzheimer’s Therapeutic Research Institute (ATRI) is to rigorously test methods for early detection of, and treatments for Alzheimer’s disease (AD) and bring effective therapeutics to the world.
The Zilkha Neurogenetic Institute (ZNI) is a cross-disciplinary hub for the neuroscience community at USC. At Zilkha, we conduct world-class science in state-of-the-art labs.
Learn more about Alzheimer’s research at Keck School of Medicine and how USC is at the forefront of effective treatments with the potential for a commercialization path in the future.